黑料网

Immunosenescence; Age-related diseases; Immunotherapy; Senescence, Immunomodulation; Immune aging markers

Introduction

is accompanied by a decline in immune function, leading to increased susceptibility to infections, impaired vaccine responses, and heightened risk of chronic inflammatory diseases. Immunosenescence, characterized by alterations in immune cell composition, function, and responsiveness, contributes to age-related changes in immune homeostasis and host defense mechanisms. Understanding the mechanisms underlying immunosenescence is essential for developing strategies to promote healthy aging and enhance immune resilience in older adults [1,2].

Methodology

Mechanisms of immunosenescence: Immunosenescence is driven by a complex interplay of intrinsic and extrinsic factors, including genetic predisposition, chronic antigenic stimulation, inflammaging and alterations in the microenvironment [3]. Aging-related changes in immune cell populations, such as thymic involution, telomere shortening and accumulation of senescent cells, impair immune surveillance, T cell repertoire diversity, and immune responses to novel antigens. Moreover, dysregulation of inflammatory signaling pathways, such as NF-κB and inflammasome activation, contributes to chronic low-grade inflammation and immune dysfunction in aging [4].

Consequences for immune function: The dysregulation of immune function in immunosenescence has profound consequences for host defense, autoimmune reactions, and tumor surveillance. Agerelated decline in innate and adaptive immune responses compromises the ability to control infections and respond to vaccination, leading to increased morbidity and mortality from infectious diseases [5- 7]. Furthermore, dysregulated immune activation contributes to the pathogenesis of chronic inflammatory conditions, autoimmune diseases, and age-related cancers, exacerbating age-related morbidity and mortality.

Implications for age-related diseases: Immunosenescence plays a central role in the pathogenesis of age-related diseases, including cardiovascular disease, neurodegenerative disorders and frailty [8]. Chronic low-grade inflammation, a hallmark of immunosenescence, contributes to the development and progression of age-related comorbidities, such as atherosclerosis, Alzheimer’s disease, and sarcopenia. Moreover, impaired immune surveillance and dysregulated immune responses increase susceptibility to age-related infections and malignancies, further exacerbating morbidity and mortality in older adults [9,10].

Discussion

Mitigating the impact of immunosenescence on healthspan and longevity requires multifaceted interventions targeting immune rejuvenation, inflammaging and age-related comorbidities. Lifestyle modifications, including regular exercise, healthy diet, and stress management, promote immune resilience and mitigate chronic inflammation associated with aging. Immunomodulatory interventions, such as vaccination, immunotherapy, and dietary supplementation, enhance immune function and reduce the risk of infections and agerelated diseases in older adults.

Conclusion

In conclusion, immunosenescence represents a critical determinant of immune function and healthspan in aging populations. By understanding the mechanisms underlying immunosenescence and its consequences for immune function and age-related diseases, researchers and clinicians can develop targeted interventions to promote healthy aging and enhance immune resilience in older adults. Through interdisciplinary approaches and personalized medicine strategies, we can harness the potential of immunosenescence research to improve health outcomes and quality of life for aging populations.

1. Bernard Cache (1995) . The MIT Press Cambridge.

, ,

2. Duarte J (1995) . World Congress on Housing Lisbon Portuga.

, ,

3. Eilouti BH (2005) . D  Zinn The International Institute of Informatics and Systemics 273-277.

, ,

4. De Waele, JJ S Dhaes S (2019) . Rev Anti Infect Ther 17: 89-97.

, ,

5. J.E. Mc Gowan (2012) . Infect Control Hosp Epidemiol 33: 331-337.

, ,

6. Brader G,Compant S,Vescio K (2017) Annu Rev Phytopathol 55:61-83.

, ,

7. Vurukonda S,Giovanardi D (2019) . Int J Mol Sci.

 , ,

8. Karam G, Chastre J,Wilcox MH (2016) . Crit Care 20: 136.

, ,

9. Perlin DS, Rautemaa R Richardson, Alastruey A (2017) . Management Lancet Infect Dis 17: 383-392.

, ,

10. Bantscheff  M, Eberhard D,  Abraham Y (2007) . Nat Biotechnol 25: 1035-1044.

, ,